Evogene
EVGN
16 hedge funds and large institutions have $10.8M invested in Evogene in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 1 closing their positions.
0.3% less ownership
Funds ownership: 2.92% → 2.62% (-0.3%)
6% less funds holding
Funds holding: 17 → 16 (-1)
29% less capital invested
Capital invested by funds: $15.2M → $10.8M (-$4.43M)
88% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 8
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$26.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$882K |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$77.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$62K |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$57.5K |
| 5 |
Goldman Sachs
New York
|
-$40.3K |
EVGN Hedge Fund Activity: Q4 2019 in Review
16 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2019, worth a combined $10.8M — down 29% from $15.2M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of EVGN and 0 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 1 added.
The largest buyer was ARK Investment Management, adding an estimated $26.8K. The largest seller was Clal Insurance, cutting an estimated $882K.
- 16 institutional investors held Evogene (EVGN) as of Q4 2019, down from 17 in Q3 2019.
- Funds reported $10.8M of Evogene stock for Q4 2019, down 29% quarter-over-quarter.
- 0 funds opened new Evogene positions in Q4 2019 and 1 closed out, a net change of -1 holder.
- The largest Evogene buyer in Q4 2019 was ARK Investment Management, an estimated $26.8K added.
- The largest Evogene seller in Q4 2019 was Clal Insurance, an estimated $882K sold.
Based on aggregated 13F filings for Q4 2019.